(Q33357562)
Statements
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors (English)
Christian Dittrich
Herlinde Dumez
Hilary Calvert
Axel Hanauske
Marije Faber
Jantien Wanders
Murray Yule
Miroslav Ravic
Pierre Fumoleau
1 November 2003